ArticleScientific reports2026
Ergothioneine promotes osteogenesis and angiogenesis through PI3K/AKT pathway and prevents glucocorticoid-induced osteonecrosis of the femoral head.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteonecrosis of the femoral head (ONFH) has a high incidence worldwide, yet effective treatments remain lacking. Oxidative stress and mitochondrial dysfunction are closely associated with ONFH development. Ergothioneine (EGT) is a potent antioxidant that can target various organs; however, its potential role in ONFH remains elusive. This study aimed to evaluate the protective effects of EGT against steroid-induced ONFH and to explore the underlying mechanisms involved. Murine bone marrow mesenchymal stem cells (BMMSCs) and human umbilical vein endothelial cells (HUVECs) were treated with EGT following dexamethasone induction. Subsequent experiments assessed cell viability and functional changes in each group. A steroid-induced rat model of ONFH was established, and the therapeutic efficacy of EGT was verified through imaging and histological analyses. Dexamethasone disrupted both the structure and function of mitochondria and induced apoptosis in BMMSCs and HUVECs. In contrast, EGT treatment activated the protein kinase B (AKT)/phosphoinositide 3-kinase (PI3K) pathway under steroid stimulation, and the cellular damage was reversed. Moreover, in the steroid-induced ONFH rat model, EGT supplementation reduced bone structural destruction and the expression of degenerative biomarkers, along with maintaining angiogenic and osteogenic marker levels. EGT exerts a protective effect against steroid-induced mitochondrial dysfunction and apoptosis by activating the AKT/PI3K-signaling pathway and maintaining osteogenesis and angiogenesis during ONFH development. These findings suggest its potential as a therapeutic agent for treating steroid-induced ONFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.